Physician profile
Eddys Disla
NPI 1679619233
$6,869.28
in general payments reported to CMS, 2019-2025
27 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $841 · 2021: $1,260 · 2022: $1,081 · 2023: $899 · 2024: $688 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,664.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,043.14 | 2019-2025 | |
| Amgen INC. | $1,005.94 | 2019-2025 | Krystexxa, Tavneos |
| Pfizer INC. | $868.32 | 2019-2025 | |
| Abbvie INC. | $661.76 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $549.66 | 2019-2025 | Taltz |
| Astrazeneca Pharmaceuticals LP | $541.33 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Ucb, INC. | $535.11 | 2019-2023 | Cimzia |
| Glaxosmithkline, LLC. | $492.63 | 2021-2025 | Benlysta, Nucala, Trelegy Ellipta |
| Mallinckrodt Hospital Products INC. | $275.66 | 2020-2021 | |
| Horizon Therapeutics Plc | $145.83 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $87.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $83.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.59 | 2021-2022 | |
| Janssen Biotech, INC. | $69.68 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $63.37 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $48.63 | 2021-2022 | |
| Celgene Corporation | $46.00 | 2019 | |
| Ironwood Pharmaceuticals, INC | $43.87 | 2020 | |
| Aurinia Pharma U.S., INC. | $39.38 | 2021 | |
| Zimmer Biomet Holdings, INC. | $35.13 | 2024 | Visco-3 Sodium Hyaluronate |
| Averitas Pharma INC. | $31.57 | 2024 | Qutenza |
| Mallinckrodt Enterprises LLC | $28.27 | 2019 | |
| Alexion Pharmaceuticals, INC. | $23.73 | 2022 | |
| Genzyme Corporation | $21.75 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $21.15 | 2021 | |
| Allergan, INC. | $11.98 | 2019 | |
| Medexus Pharma, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddys Disla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.